Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?
- 1 November 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Diabetes Reviews
- Vol. 17 (9), 1-11
- https://doi.org/10.2174/1573399817666201228120725
Abstract
Introduction/Aims: South Asians experience more type 2 diabetes, which is earlier in onset and with more rapid glycaemic deterioration, although average body mass indices are lower than in whites. Cardiovascular outcomes from diabetes drug trials are now reported as standard, with data from newer therapies influencing patient management. However, less is known of the effect of such therapies in South Asians. The aim of this narrative review was to extract, wherever possible, the glucose-lowering efficacy and cardiovascular and renal outcome data for these therapies in South Asians. Discussion/Conclusions: Despite the higher prevalence and global burden of type 2 diabetes and adverse outcomes in South Asians, they remain underrepresented in global trials. Even when recruited, the current method of classifying ethnicity does not commonly allow South Asian data to be extracted and reported separately from all Asians. Interrogation of available trial data suggests broadly comparable effects on glycaemia and weight in Asians to other ethnicities with use of glucagon-like peptide 1 receptor agonists (GLP-1RA), but a potentially early, albeit marginally, greater glycaemia benefit with Dipeptidyl peptidase-4 inhibitors (DPP4i) which may not be sustained. Furthermore, there appears a potentially greater glycaemia benefit with use of sodium-glucose transport protein 2 inhibitors (SGLT2i) in Asians compared to whites. Whether such findings are true in all Asians subgroups requires further direct study. For cardiovascular outcomes, available data suggest at least comparable and potentially greater outcome benefits in Asians; point estimates were more favourable for Asians in the vast majority of GLP-1RA and SGLT2i outcome trials. It was, however, impossible to determine whether the effects were similar across all Asian subgroups. We conclude that trialists should be encouraged to record ethnicity with better granularity to allow differing ethnic groups data to be better interrogated. In the meantime, doctors should, where possible, confidently follow newer guidelines for the use of newer glucose lowering agents for treating glycaemia and the prevention of cardiovascular and cardiorenal complications in South Asian people with type 2 diabetes.Keywords
Funding Information
- British Heart Foundation Research Excellence Award (RE/18/6/34217)
This publication has 67 references indexed in Scilit:
- Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trialsBMJ Open, 2014
- Dapagliflozin as Monotherapy in Drug-Naive Asian Patients With Type 2 Diabetes Mellitus: A Randomized, Blinded, Prospective Phase III StudyClinical Therapeutics, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusThe New England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesThe New England Journal of Medicine, 2013
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 DiabetesAnnals of Internal Medicine, 2013
- Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic ReviewClinical Therapeutics, 2012
- Cardiovascular Disease in Type 2 Diabetes From Population to Man to MechanismsDiabetes Care, 2010
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsThe Lancet, 2009
- Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Research and Clinical Practice, 2009
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesThe New England Journal of Medicine, 2007